You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Aminoglycosides with reduced ototoxicity via miRNA targeting

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ototoxici ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. A New Non-Invasive Approach for Accessing Pulmonary Arterial Stiffness in Patients with Pulmonary Hypertension

    SBC: Arcus-Med LLC            Topic: NHLBI

    Pulmonary hypertensionPHis a disease affecting approximatelyof the general population that is characterized by abnormally elevated mean pulmonary artery pressuremPAPand pulmonary vascular resistancePVRIf left untreatedPH can ultimately lead to right heart failure and deathCurrent diagnostic approaches utilize invasive right heart catheterizationRHCto measure mPAP and PVREarly detection of PH leads ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel remedy for periodontal bone loss

    SBC: Periomics Care LLC            Topic: NIDCR

    Abstract Periodontitis is a common chronic inflammatory disease characterized by destruction of the supporting structures of the teeththe periodontal ligament and alveolar boneThe total prevalence of periodontitis in adults agedyears and older wasrepresenting aboutmillion adults agedyears and olderandin adults agedyears and older in the U SEpidemiological data confirm that diabetes is a major risk ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. A portable multi-parametric optical spectroscopy device for key vascular and metabolic endpoints monitoring in small animals

    SBC: Zenalux Biomedical, Inc.            Topic: OD

    Altered vascularity and deregulated metabolism are two important cancer hallmarksInterest in therapeutically exploiting these functional endpoints continues to growsince metabolism and vasculature significantly impact a tumor s fateThere is growing demand for systems level technologies that measure tumor metabolism within an intact microenvironment to inform strategies to prevent resistancerecurre ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. A recombinant matrix to improve autologous tissue grafts

    SBC: inSoma Bio Inc            Topic: 102

    Abstract The objective of this proposal is to validate a new regenerative tissue matrix which studies to date indicate may be possible of redefining the limits of autologous fat graftingThis objective is motivated by the currently limited surgical options available to themillion patients undergoing reconstructive plastic surgery each year to treat body disfigurement and dysfunctionA core component ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Automated CRISPR Screening Using the CellRaft Technology

    SBC: Cell Microsystems, Inc.            Topic: 400

    Project SummaryGenome wide functional genetics has been recently made possible by pooled library based CRISPR Casgene editing technologyBy randomly knocking out thousands of geneslarge scale screens can be conducted for functional geneticsdrug sensitivity and other phenotypesCurrently howeverthis forward genetic approach is largely relegated to live dead screens in mammalian cellsImproving the sop ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Correction of Splicing Defects in Cystic Fibrosis with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds

    SBC: Initos Pharmaceuticals LLC            Topic: NCATS

    ABSTRACT The pathogenesis of Cystic FibrosisCFis caused by mutations in the gene for CFTRa cAMP activated chloride channel that regulates salt and water transport in epithelial tissuesespecially those in the airwaysRecent progress has resulted in small molecule therapeutic agents that partially correct defects in the CFTR protein due to certain mutationsHoweverin a substantial fraction of CF patie ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Developing and validating a podocyte cell-based diagnostic assay for identifying recurrent focal and segmental glomerulosclerosis patients

    SBC: InDepth Pharmaceuticals, LLC            Topic: 400

    Diagnosing glomerular diseases accurately and in timely fashion is key to developing a successful treatment plan and thereby prevent their progression to ESRDend stage renal diseaseHowevertheir successful diagnosis remains challenging due to the complex diagnostic procedures used including invasive renal biopsiesThusthere is a compelling need to develop simplified procedures to detect glomerular d ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Development and in vitro validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Development of an Antigen Capture Assay for Babesia microti

    SBC: Biopeptides, Corp            Topic: NIAID

    DESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government